|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
|
Fulcrum Therapeutics, Inc. (FULC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
| |
Company
Roster
|
|
Total
Insiders : |
22 |
|
|
|
Total
Direct Shares :
|
6,476,246 |
|
|
Total
Indirect Shares :
|
20,873,817 |
| |
%
Held by Insiders:
|
10.28% |
|
|
| |
| Filer's Name |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
  Tourangeau Greg |
|
2024-03-08 |
11,807 |
2022-05-06 |
0 |
| Sapir Alex |
|
2024-03-04 |
43,360 |
2024-03-04 |
0 |
| Gould Robert J |
Interim President & CEO, Director |
2023-01-13 |
499,864 |
|
0 |
| Tepper Robert I |
10% Owner |
2022-12-13 |
2,118,391 |
2022-12-13 |
2,343,154 |
| Levin Mark J |
Director, 10% Owner |
2021-11-10 |
75,800 |
2021-11-10 |
3,970,625 |
| Stuart Bryan |
See Remarks, Director |
2021-08-11 |
0 |
2021-08-10 |
0 |
| Moxham Christopher |
Chief Scientific Officer |
2021-08-10 |
0 |
2021-08-10 |
0 |
| Geraghty James A |
Director |
2021-06-28 |
90,714 |
|
0 |
| Morabito Christopher |
Chief Medical Officer |
2021-06-28 |
1,100 |
2021-06-28 |
0 |
| Oltmans Curtis Gale |
SVP, General Counsel |
2021-06-28 |
1,088 |
2021-06-28 |
0 |
| Thomson Peter G. |
VP Finance & Accounting |
2021-02-22 |
15,212 |
2021-06-28 |
2,300 |
| Wallace Owen B. |
Chief Scientific Officer |
2020-09-14 |
133,438 |
|
0 |
| Cadavid Diego |
SVP Clinical Development |
2020-07-01 |
65,714 |
|
0 |
| Maris William J |
10% Owner |
2019-07-22 |
464,285 |
2019-07-22 |
0 |
| Casdin Eli |
10% Owner |
2019-07-22 |
0 |
2019-07-22 |
604,285 |
| Glaxosmithkline Plc |
|
2019-07-22 |
0 |
2019-07-22 |
1,785,714 |
| 6 Dimensions Capital, L.p. |
10% Owner |
2019-07-22 |
559,821 |
2019-07-22 |
0 |
| Sanofi-Aventis |
10% Owner |
2019-07-22 |
0 |
2019-07-22 |
558,035 |
| Trv Gp Iv, Llc |
10% Owner |
2019-07-22 |
2,343,154 |
2019-07-22 |
0 |
| Collins James J. |
Director |
2019-07-17 |
23,571 |
|
0 |
| Ezekowitz Alan |
Director |
2019-07-17 |
28,927 |
|
0 |
| Shah Rajeev M. |
10% Owner |
|
0 |
2023-01-20 |
11,609,704 |
|
|
